Phaseline

Companies › Sinfatin

Sinfatin: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Rimonabant
Cannabinoid CB1 receptor antagonist
CNR1Phase 1Cervical Spinal Cord InjuryAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07843108RimonabantPhase 1Cervical Spinal Cord InjuryNeurologyAug 2027

Targets

CNR1 (1)

Companies with the same targets

Jazz Pharmaceuticals IGC Pharma Zynerba Pharmaceuticals Skye Bioscience PleoPharma Laboratorio Elea Phoenix Bazelet Nehushtan Incannex Healthcare Vertanical Alasht Pharmed

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.